DOCSLIB.ORG

Modern Management of Primary Systemic Vasculitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modern Management of Primary Systemic Vasculitis CME: CLINICAL PRACTICE AND ITS BASIS The aetiology is unknown but, like most autoimmune diseases, involves a complex interaction between environmental Rheumatology factors and a genetically predisposed host. Edited by Richard Watts DM FRCP, Investigation and diagnosis of Consultant Rheumatologist, Ipswich Hospital NHS Trust; Senior Lecturer, primary systemic vasculitis School of Medicine, Health Policy, University of East Anglia (Table 2) Symptoms can be non-specific in the early phases of the disease and a high Background index of suspicion is required. Symptoms Modern management that should prompt consideration of a The systemic vasculitides are a group of diagnosis of vasculitis are unexplained of primary systemic heterogeneous, relatively uncommon systemic disturbance, arthritis or conditions characterised by inflamma- arthralgia, polymyalgia, episcleritis, vasculitis tion and necrosis of blood vessel walls. neuropathy, microscopic haematuria, They are classified according to vessel pulmonary infiltrates or nodules and size (Table 1).1 Primary systemic vas- maturity-onset asthma. Chloe Lapraik MB MRCP, Specialist Registrar culitis (PSV) (comprising Wegener’s Acute-phase reactants such as in Rheumatology, Luton and Dunstable granulomatosis (WG), Churg-Strauss C-reactive protein and erythrocyte sedi- Hospital syndrome (CSS) and microscopic mentation rate are typically elevated in Richard Watts DM FRCP, Consultant polyangiitis (MPA)) typically involves the acute phase. Urinalysis should be Rheumatologist, Ipswich Hospital NHS Trust; medium and small vessels and is associ- performed as soon as the diagnosis of Senior Lecturer, School of Medicine, Health Policy and Practice, University of East Anglia ated with the presence of antineutrophil vasculitis is suspected because renal cytoplasmic antibodies (ANCA). This involvement may progress silently and it David GI Scott MD FRCP, Consultant group is sometimes described as ANCA- is associated with a worse prognosis. Full Rheumatologist, Norfolk and Norwich University Hospital NHS Trust; Honorary associated vasculitis (AAV). blood count should be measured, Professor, School of Medicine, Health Policy Most data on the incidence and preva- looking particularly for eosinophilia. It and Practice, University of East Anglia lence of PSV have come from Europe. is essential to investigate critical organ The consensus is that: function for renal, cardiac and pul- Clin Med 2007;7:43–7 • the overall annual incidence is monary involvement, with appropriate approximately 10–20 per million organ-specific tests (Fig 1). the peak age of onset is 65–74 years Autoantibodies including ANCA are • useful in the appropriate clinical setting. It it is slightly more common in men • is important to recognise that a negative 2,3 • it is very rare in childhood. ANCA does not exclude vasculitis and a positive ANCA does not necessarily prove 4 Table 1. Classification of systemic vasculitis. Reprinted with permission from Elsevier.1 vasculitis. Infection should be excluded by blood Vasculitis culture and appropriate serology because Dominant vessel Primary Secondary treatment for PSV involves intense immunosuppression. Large arteries Giant cell arteritis Aortitis associated with RA, The choice of biopsy site depends on Takayasu’s arteritis infection (eg syphilis, TB) the clinical features, but skin and renal Medium arteries Classical PAN Hepatitis B-associated PAN biopsies are often helpful for diagnosis. Kawasaki disease Treatment should not be delayed for a Small vessels and Wegener’s granulomatosis Vasculitis secondary to RA, biopsy if there are strong clinical grounds medium arteries Churg-Strauss syndrome SLE, Sjögren’s syndrome, for a diagnosis of vasculitis. Microscopic polyangiitis drugs, infection (eg HIV) Imaging investigations including Small vessels Henoch-Schonlein purpura Drugs Cryoglobulinaemia Hepatitis C-associated angiography should be carefully consid- Cutaneous leucocytoclastic infection ered in appropriate cases. Coeliac axis angiitis angiography has an important role in the diagnosis of polyarteritis nodosa. PAN = polyarteritis nodosa; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; TB = tuberculosis. There are a number of conditions that may mimic systemic vasculitis and these Clinical Medicine Vol 7 No 1 January/February 2007 43 CME Rheumatology Table 2. Investigation of vasculitis. must be considered in the differential diagnosis (Table 3). Assessment of inflammation Blood count and differential cell count (total white cell count, eosinophils) Acute-phase response (ESR, CRP) Treatment Liver function Assessment of organ involvement Urinalysis (proteinuria, haematuria, casts) The natural history of untreated PSV is Renal function (creatinine clearance, 24-hour protein, of a rapidly progressive, usually fatal dis- excretion, biopsy) ease. With modern treatment regimens Chest radiograph Liver function the five-year survival rates are 45% for 5 Nervous system (nerve conduction studies, biopsy) MPA, 76% for WG and 68% for CSS. Muscle (EMG, creatinine kinase, biopsy) The European Vasculitis Study Group Cardiac function (ECG, echocardiography) (EUVAS) has recently completed a series Gut (angiography) of multicentre randomised controlled Skin (biopsy) trials (RCTs).6 Detailed guidelines for the Serological tests ANCA (including proteinase 3, myeloperoxidase) management of the PSV have recently Antinuclear antibodies Rheumatoid factor been developed by the British Society for Anticardiolipin antibodies Rheumatology.7 Complement Current treatment is based on Cryoglobulins assessing severity and extent of disease, Differential diagnosis Blood cultures subdividing the disease into three groups Viral serology (HBV, HCV, HIV, CMV) as adopted by EUVAS (Table 4). Echocardiography (2-dimensional, transoesophageal or both) Treatment can be divided into three stages: induction, consolidation and ANCA = antineutrophil cytoplasmic antibody; CMV = cytomegalovirus; CRP = C-reactive protein; EMG = maintenance of remission. electromyography; ESR = erythrocyte sedimentation rate; HBV = hepatitis B virus; HCV = hepatitis C virus. Treatment for remission induction Localised/early systemic disease Cyclophosphamide (CYC) (maximum dose oral 200 mg/day or intravenous pulse 15 mg/kg) and methotrexate (MTX) (maximum 20–25 mg/week) are the most established treatments for this category. MTX is effective but may be associated with a higher relapse rate; any evidence of progression or relapse should be treated with CYC.8 Localised disease can have significant local destructive consequences and these patients require CYC treatment. Generalised/threatened organ involvement Initial treatment of patients with gener- alised/organ-threatening disease should include CYC and steroids. CYC may be given as continuous low-dose oral treat- ment (2 mg/kg/day, maximum 200 mg/day) or by intravenous (iv) pulse (15 mg/kg, maximum 1,500 mg per Fig 1. Algorithm for the management of primary systemic vasculitis (PSV).7 pulse), initially at two-weekly intervals AZA = azathioprine; creat = creatinine; CYC = cyclophosphamide; MTX = methotrexate; and then three-weekly. Dose reduc- Pred = prednisolone. tions should be made for age and renal 44 Clinical Medicine Vol 7 No 1 January/February 2007 CME Rheumatology function. The recently completed EUVAS Table 3. Differentiation to be made from conditions that may mimic primary systemic 1 trial of pulse versus continuous low-dose vasculitis. Reprinted with permission from Elsevier. oral CYC showed no difference in remis- Multisystem disease Infection Subacute bacterial endocarditis sion rates and no increased risk of relapse Neisseria in the iv treated patients.9 Continuous Rickettsiae low-dose oral CYC was associated with a Malignancy Metastatic carcinoma Paraneoplastic higher total CYC dosage and a significant Other Sweet’s syndrome increase in infection risk. The cumulative Occlusive vasculopathy Embolic Cholesterol crystals dose of CYC was lower for the iv pulse Atrial myoma regimen than for the continuous oral Infection regimen when administered for the same Calciphylaxis period of time. Thrombotic Antiphospholipid syndrome Procoagulant states Current clinical practice considers Cryofibrinogenaemia transfer to maintenance therapy after Others Ergot 3–6 months of CYC therapy if successful Radiation disease remission has been achieved. The Degos syndrome aim should be for a maximum duration Severe Raynaud’s Acute digital loss of therapy of six months where successful Buerger’s disease disease remission has been achieved. Angiographic Aneurysmal Fibromuscular dysplasia Neurofibromatosis Severe/life-threatening disease Occlusion Coarctation Patients with PSV presenting with severe renal failure (creatinine >500 µmol/l) tively high doses (1 mg/kg up to about and either AZT or MTX substituted. A should be treated with CYC (either 60 mg) and tapered to about 10 mg/day recent trial comparing CYC and AZT pulsed iv or continuous low-dose oral) at six months.10 Steroids (250–500 mg iv found them equally effective at main- and steroids, with adjuvant plasma methylprednisolone) are sometimes taining remission, with similar relapse exchange.10 Plasma exchange should also given with the first two pulses of iv CYC. rates but increased toxicity in the CYC be considered in those with other life- group.11 MTX may be used in patients threatening manifestations of disease Patients intolerant of intolerant of AZT, with mycophenolate such as pulmonary haemorrhage. cyclophosphamide or leflunomide as
Load more

Recommended publications
  • Psoriasis, a Systemic Disease Beyond the Skin, As Evidenced by Psoriatic Arthritis and Many Comorbities
    1 Psoriasis, a Systemic Disease Beyond the Skin, as Evidenced by Psoriatic Arthritis and Many Comorbities – Clinical Remission with a Leishmania Amastigotes Vaccine, a Serendipity Finding J.A. O’Daly Astralis Ltd, Irvington, NJ USA 1. Introduction Psoriasis is a systemic chronic, relapsing inflammatory skin disorder, with worldwide distribution, affects 1–3% of the world population, prevalence varies according to race, geographic location, and environmental factors (Chandran & Raychaudhuri, 2010; Christophers & Mrowietz, 2003; Farber & Nall, 1974). In Germany, 33,981 from 1,344,071 continuously insured persons in 2005 were diagnosed with psoriasis; thus the one year prevalence was 2.53% in the study group. Up to the age of 80 years the prevalence rate (range: 3.99-4.18%) was increasing with increasing age and highest for the age groups from 50 to 79 years The total rate of psoriasis in children younger than 18 years was 0.71%. The prevalence rates increased in an approximately linear manner from 0.12% at the age of 1 year to 1.2% at the age of 18 years (Schäfer et al., 2011). In France, a case-control study in 6,887 persons, 356 cases were identified (5.16%), who declared having had psoriasis during the previous 12 months (Wolkenstein et al., 2009). The prevalence of psoriasis analyzed across Italy showed that 2.9% of Italians declared suffering from psoriasis (regional range: 0.8-4.5%) in a total of 4109 individuals (Saraceno et al., 2008). The overall rate of comorbidity in subjects with psoriasis aged less than 20 years was twice as high as in subjects without psoriasis.
    [Show full text]
  • ANCA--Associated Small-Vessel Vasculitis
    ANCA–Associated Small-Vessel Vasculitis ISHAK A. MANSI, M.D., PH.D., ADRIANA OPRAN, M.D., and FRED ROSNER, M.D. Mount Sinai Services at Queens Hospital Center, Jamaica, New York and the Mount Sinai School of Medicine, New York, New York Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis is the most common primary sys- temic small-vessel vasculitis to occur in adults. Although the etiology is not always known, the inci- dence of vasculitis is increasing, and the diagnosis and management of patients may be challenging because of its relative infrequency, changing nomenclature, and variability of clinical expression. Advances in clinical management have been achieved during the past few years, and many ongoing studies are pending. Vasculitis may affect the large, medium, or small blood vessels. Small-vessel vas- culitis may be further classified as ANCA-associated or non-ANCA–associated vasculitis. ANCA–asso- ciated small-vessel vasculitis includes microscopic polyangiitis, Wegener’s granulomatosis, Churg- Strauss syndrome, and drug-induced vasculitis. Better definition criteria and advancement in the technologies make these diagnoses increasingly common. Features that may aid in defining the spe- cific type of vasculitic disorder include the type of organ involvement, presence and type of ANCA (myeloperoxidase–ANCA or proteinase 3–ANCA), presence of serum cryoglobulins, and the presence of evidence for granulomatous inflammation. Family physicians should be familiar with this group of vasculitic disorders to reach a prompt diagnosis and initiate treatment to prevent end-organ dam- age. Treatment usually includes corticosteroid and immunosuppressive therapy. (Am Fam Physician 2002;65:1615-20. Copyright© 2002 American Academy of Family Physicians.) asculitis is a process caused These antibodies can be detected with indi- by inflammation of blood rect immunofluorescence microscopy.
    [Show full text]
  • Celiac Disease and Nonceliac Gluten Sensitivitya Review
    Clinical Review & Education JAMA | Review Celiac Disease and Nonceliac Gluten Sensitivity A Review Maureen M. Leonard, MD, MMSc; Anna Sapone, MD, PhD; Carlo Catassi, MD, MPH; Alessio Fasano, MD CME Quiz at IMPORTANCE The prevalence of gluten-related disorders is rising, and increasing numbers of jamanetwork.com/learning individuals are empirically trying a gluten-free diet for a variety of signs and symptoms. This review aims to present current evidence regarding screening, diagnosis, and treatment for celiac disease and nonceliac gluten sensitivity. OBSERVATIONS Celiac disease is a gluten-induced immune-mediated enteropathy characterized by a specific genetic genotype (HLA-DQ2 and HLA-DQ8 genes) and autoantibodies (antitissue transglutaminase and antiendomysial). Although the inflammatory process specifically targets the intestinal mucosa, patients may present with gastrointestinal signs or symptoms, extraintestinal signs or symptoms, or both, Author Affiliations: Center for Celiac suggesting that celiac disease is a systemic disease. Nonceliac gluten sensitivity Research and Treatment, Division of is diagnosed in individuals who do not have celiac disease or wheat allergy but who Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for have intestinal symptoms, extraintestinal symptoms, or both, related to ingestion Children, Boston, Massachusetts of gluten-containing grains, with symptomatic improvement on their withdrawal. The (Leonard, Sapone, Catassi, Fasano); clinical variability and the lack of validated biomarkers for nonceliac gluten sensitivity make Celiac Research Program, Harvard establishing the prevalence, reaching a diagnosis, and further study of this condition Medical School, Boston, Massachusetts (Leonard, Sapone, difficult. Nevertheless, it is possible to differentiate specific gluten-related disorders from Catassi, Fasano); Shire, Lexington, other conditions, based on currently available investigations and algorithms.
    [Show full text]
  • Conditions Related to Inflammatory Arthritis
    Conditions Related to Inflammatory Arthritis There are many conditions related to inflammatory arthritis. Some exhibit symptoms similar to those of inflammatory arthritis, some are autoimmune disorders that result from inflammatory arthritis, and some occur in conjunction with inflammatory arthritis. Related conditions are listed for information purposes only. • Adhesive capsulitis – also known as “frozen shoulder,” the connective tissue surrounding the joint becomes stiff and inflamed causing extreme pain and greatly restricting movement. • Adult onset Still’s disease – a form of arthritis characterized by high spiking fevers and a salmon- colored rash. Still’s disease is more common in children. • Caplan’s syndrome – an inflammation and scarring of the lungs in people with rheumatoid arthritis who have exposure to coal dust, as in a mine. • Celiac disease – an autoimmune disorder of the small intestine that causes malabsorption of nutrients and can eventually cause osteopenia or osteoporosis. • Dermatomyositis – a connective tissue disease characterized by inflammation of the muscles and the skin. The condition is believed to be caused either by viral infection or an autoimmune reaction. • Diabetic finger sclerosis – a complication of diabetes, causing a hardening of the skin and connective tissue in the fingers, thus causing stiffness. • Duchenne muscular dystrophy – one of the most prevalent types of muscular dystrophy, characterized by rapid muscle degeneration. • Dupuytren’s contracture – an abnormal thickening of tissues in the palm and fingers that can cause the fingers to curl. • Eosinophilic fasciitis (Shulman’s syndrome) – a condition in which the muscle tissue underneath the skin becomes swollen and thick. People with eosinophilic fasciitis have a buildup of eosinophils—a type of white blood cell—in the affected tissue.
    [Show full text]
  • Comorbidities in Psoriasis: the Recognition of Psoriasis As a Systemic Disease and Current Management
    Review Derleme 71 DOI: 10.4274/turkderm.09476 Turkderm-Turk Arch Dermatol Venereology 2017;51:71-7 Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım Göknur Kalkan Ankara Yıldırım Beyazıt University Faculty of Medicine, Department of Dermatology, Ankara, Turkey Abstract Psoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past. There are several classifications of the comorbidities which are more common in patients with moderate to severe psoriasis. Simply, comorbidities can be classified as classic, emerging, related to lifestyle, related to treatment. They can also be categorized as medical comorbidities, psychiatric/psychologic comorbidities, and behaviors contributing to medical and psychiatric comorbidities. In this review, providing early diagnosis and treatment of comorbidities, learning screening recommendations for early detection and long-term disease control and improvement in life quality by integrated, multidisciplinary approach were targeted. Keywords: Psoriasis, comorbidity, systemic disease Öz Tüm dünyada %2-3 oranında görülme sıklığına sahip psoriazis, geçmişte sadece deriye sınırlı kabul edilirken, günümüzde birçok komorbiditenin eşlik ettiği kronik sistemik enflamatuvar bir hastalık olarak ele alınmaktadır. Orta-şiddetli düzeyde
    [Show full text]
  • Vasculitis: Pearls for Early Diagnosis and Treatment of Giant Cell Arteritis
    Vasculitis: Pearls for early diagnosis and treatment of Giant Cell Arteritis Mary Beth Humphrey, MD, PhD Professor of Medicine McEldowney Chair of Immunology [email protected] Office Phone: 405 271-8001 ext 35290 October 2019 Relevant Disclosure and Resolution Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made regarding relevant financial relationships with commercial interests within the last 12 months. Mary Beth Humphrey I have no relevant financial relationships or affiliations with commercial interests to disclose. Experimental or Off-Label Drug/Therapy/Device Disclosure I will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA. Objectives • To recognize early signs of vasculitis. • To discuss Tocilizumab (IL-6 inhibitor) as a new treatment option for temporal arteritis. • To recognize complications of vasculitis and therapies. Professional Practice Gap Gap 1: Application of imaging recommendations in large vessel vasculitis Gap 2: Application of tocilizimab in treatment of giant cell vasculitis Cranial Symptoms Aortic Vision loss Aneurysm GCA Arm PMR Claudication FUO Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Giant Cell Arteritis • Most common form of systemic vasculitis in adults – Incidence: ~ 1/5,000 persons > 50 yrs/year – Lifetime risk: 1.0% (F) 0.5% (M) • Cause: unknown At risk: Women (80%) > men (20%) Northern European ancestry>>>AA>Hispanics Age: average age at onset ~73 years Smoking: 6x increased risk Kermani TA, et al Ann Rheum Dis.
    [Show full text]
  • Audio Vestibular Gluco Corticoid General and Local Or Cytotoxic Agents
    Global Journal of Otolaryngology ISSN 2474-7556 Case Report Glob J Otolaryngol Volume 13 Issue 5 - March 2018 Copyright © All rights are reserved by Cristina Otilia Laza DOI: 10.19080/GJO.2018.13.555871 Autoimmune Granulomatosis with Polyangiitis or Wegener Granulomatosis Cristina Otilia Laza1*, Gina Enciu2, Luminita Micu2 and Maria Suta3 1Department of ENT, County Clinical Emergency Hospital of Constanta, Romania 2Department of Anatomo pathology, County Clinical Emergency Hospital of Constanta, Romania 3Department of Rheumatology, County Clinical Emergency Hospital of Constanta, Romania Submission: February 19, 2018; Published: March 14, 2018 *Corresponding author: Cristina Otilia Laza, Department of ENT, County Clinical Emergency Hospital of Constanta, Romania, Email: Abstract Granulomatosis with polyangiitis, formerly known as Wegener granulomatosis, is a disease that typically consists of a triad of airway necrotizing granulomas, systemic vasculitis, and focal glomerulonephritis. If the disease does not involve the kidneys, it is called limited granulomatosis with polyangiitis. The etiology and pathogenesis of WG are unknown. Infectious, genetic, and environmental risk factors and combinations thereof have been proposed. The evidence to date suggests that WG is a complex, immune-mediated disorder in which tissue production of ANCA, directed against antigens present within the primary granules of neutrophils and monocytes; these antibodies produce tissueinjury damageresults from by interacting the interplay with of primedan initiating neutrophils inflammatory and endothelial event and cells a highly The purposespecific immune of this article response. is to Part present of this 4 patients response all consists diagnosed of the in our department ,with head and neck lesions ,every case with his manifestation and response to the treatment .We consider that a well trained ENT specialist must be able to diagnose and recognize such a disease but this requires knowledge and hard work.
    [Show full text]
  • Understanding the Cryoglobulinemias
    Current Rheumatology Reports (2019) 21:60 https://doi.org/10.1007/s11926-019-0859-0 VASCULITIS (L ESPINOZA, SECTION EDITOR) Understanding the Cryoglobulinemias Alejandro Fuentes1 & Claudia Mardones1 & Paula I. Burgos1 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of the Review Cryoglobulins are immunoglobulins with the ability to precipitate at temperatures <37 °C. They are related to hematological disorders, infections [especially hepatitis C virus (HCV)], and autoimmune diseases. In this article, the state of the art on Cryoglobulinemic Vasculitis (CV), in a helpful and schematic way, with a special focus on HCV related Mixed Cryoglobulinemia treatment are reviewed. Recent Findings Direct – acting antivirals (DAA) against HCV have emerged as an important key in HCV treatment to related Cryoglobulinemic Vasculitis, and should be kept in mind as the initial treatment in non–severe manifestations. On the other hand, a recent consensus panel has published their recommendations for treatment in severe and life threatening manifestations of Mixed Cryoglobulinemias. Summary HCV-Cryoglobulinemic vasculitis is the most frequent form of CV. There are new treatment options in HCV-CV with DAA, with an important number of patients achieving complete response and sustained virologic response (SVR). In cases of severe forms of CV, treatment with Rituximab and PLEX are options. The lack of data on maintenance therapy could impulse future studies in this setting. Keywords HCV . Mixed Cryoglobulinemia . Type I Cryoglobulinemia . gC1qR . Direct-acting antivirals . Rituximab Introduction and Definitions tion of the total pool of cryoprecipitable immunocomplexes in targeted vessels and due to false negative results owing to im- Cryoglobulins are immunoglobulins (Ig) that precipitate in vitro proper blood sampling or inadequate laboratory processes [4].
    [Show full text]
  • A Case of Cryoglobulinemia After Successful Hepatitis C Virus Treatment
    ISSN: 2572-3286 Farmakis et al. J Clin Nephrol Ren Care 2020, 6:050 DOI: 10.23937/2572-3286.1510050 Volume 6 | Issue 1 Journal of Open Access Clinical Nephrology and Renal Care CASE REPORT A Case of Cryoglobulinemia after Successful Hepatitis C Virus Treatment 1* 1 1 Christopher Farmakis, MD , Victor Canela, DO , Leigh Hunter, MD, FACP , Brooke Mills, Check for MD1, Ravina Linenfelser, DO2 and Kyawt Shwin, MD2 updates 1Department of Internal Medicine, Methodist Dallas Medical Center, Dallas, TX 75203, USA 2Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 3Rheumatology Section, Veterans Affairs North Texas Health Care System, Dallas, TX 75216, USA 4The Clinical Research Institute, Methodist Dallas Medical Center, Dallas, TX 75203, USA The authors thank Anne Murray, PhD of The Clinical Research Institute at Methodist Health System for providing medical writing and editorial support *Corresponding author: Christopher Farmakis, MD, PGY-3, Department of Internal Medicine Resident, Methodist Dallas Medical Center, 1441 N Beckley Avenue, Dallas, Texas 75203, USA, Tel: (214)-947-8181 multiple organ systems including the skin, joints, Abstract peripheral nervous system, and kidneys [1]. In most Cryoglobulinemic vasculitis is a complex and destructive cases, the disease is characterized by mixed cryo- disease process that affects multiple organ systems. The pathophysiology includes formation of immune complex globulinemiain which abnormal immune complexes, deposits that create an inflammatory response in various termed cryoglobulins, composed of IgM, IgA, and/or organs, yielding distinct presentations such as purpura, rheumatoid factor aggregate in the blood. Cryoglob- arthralgias, neuropathy, fever, and pulmonary vasculitis. ulins can be found in chronic infections, lymphopro- Over 30% of cryoglobulinemic vasculitis cases present with glomerulonephritis, which carries a worse prognosis.
    [Show full text]
  • Oral and Maxillo-Facial Manifestations of Systemic Diseases: an Overview
    medicina Review Oral and Maxillo-Facial Manifestations of Systemic Diseases: An Overview Saverio Capodiferro *,† , Luisa Limongelli *,† and Gianfranco Favia Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Piazza G. Cesare, 11, 70124 Bari, Italy; [email protected] * Correspondence: [email protected] (S.C.); [email protected] (L.L.) † These authors contributed equally to the paper. Abstract: Many systemic (infective, genetic, autoimmune, neoplastic) diseases may involve the oral cavity and, more generally, the soft and hard tissues of the head and neck as primary or secondary localization. Primary onset in the oral cavity of both pediatric and adult diseases usually represents a true challenge for clinicians; their precocious detection is often difficult and requires a wide knowledge but surely results in the early diagnosis and therapy onset with an overall better prognosis and clinical outcomes. In the current paper, as for the topic of the current Special Issue, the authors present an overview on the most frequent clinical manifestations at the oral and maxillo-facial district of systemic disease. Keywords: oral cavity; head and neck; systemic disease; oral signs of systemic diseases; early diagnosis; differential diagnosis Citation: Capodiferro, S.; Limongelli, 1. Introduction L.; Favia, G. Oral and Maxillo-Facial Oral and maxillo-facial manifestations of systemic diseases represent an extensive and Manifestations of Systemic Diseases: fascinating study, which is mainly based on the knowledge that many signs and symptoms An Overview. Medicina 2021, 57, 271. as numerous systemic disorders may first present as or may be identified by head and https://doi.org/10.3390/ neck tissue changes.
    [Show full text]
  • Cutaneous Manifestations of Systemic Disease
    Cutaneous Manifestations of Systemic Disease Dr. Lloyd J. Cleaver D.O. FAOCD FAAD Northeast Regional Medical Center A.T.Still University/KCOM Assistant Vice President/Professor ACOI Board Review Disclosure I have no financial relationships to disclose I will not discuss off label use and/or investigational use in my presentation I do not have direct knowledge of AOBIM questions I have been granted approvial by the AOA to do this board review Dermatology on the AOBIM ”1-4%” of exam is Dermatology Table of Test Specifications is unavailable Review Syllabus for Internal Medicine Large amount of information Cutaneous Multisystem Cutaneous Connective Tissue Conditions Connective Tissue Diease Discoid Lupus Erythematosus Subacute Cutaneous LE Systemic Lupus Erythematosus Scleroderma CREST Syndrome Dermatomyositis Lupus Erythematosus Spectrum from cutaneous to severe systemic involvement Discoid LE (DLE) / Chronic Cutaneous Subacute Cutaneous LE (SCLE) Systemic LE (SLE) Cutaneous findings common in all forms Related to autoimmunity Discoid LE (Chronic Cutaneous LE) Primarily cutaneous Scaly, erythematous, atrophic plaques with sharp margins, telangiectasias and follicular plugging Possible elevated ESR, anemia or leukopenia Progression to SLE only 1-2% Heals with scarring, atrophy and dyspigmentation 5% ANA positive Discoid LE (Chronic Cutaneous LE) Scaly, atrophic plaques with defined margins Discoid LE (Chronic Cutaneous LE) Scaly, erythematous plaques with scarring, atrophy, dyspigmentation DISCOID LUPUS Subacute Cutaneous
    [Show full text]
  • Microscopic Polyangiitis1
    Microscopic polyangiitis1 Author: Professor J. Charles Jennette2 Creation Date: October 2002 Scientific Editor: Professor Loïc Guillevin 1This text was adapted from: Jennette JC, Thomas DB, Falk RJ. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol. 2001;18:3-13. 2Department of Pathology and Laboratory Medicine, University of North Carolina, 303 Brinkhous-Bullitt Building, NC 27599-7525 Chapel Hill, United States. [email protected] Abstract Keywords Disease name Definition Differential diagnosis Frequency Clinical manifestation Diagnostic methods Treatment Unresolved questions References Abstract Microscopic polyangiitis (MPA) refers to a necrotizing systemic vasculitis with few or no immune deposits that affects small vessels (ie, capillaries, venules and arterioles). Arteries, especially small arteries, are often but not always involved. Vessels of any type in any organ can be affected, resulting in a wide variety of signs and symptoms, and nonspecific clinical manifestations. Common signs and symptoms include nephritis, pulmonary hemorrhage, purpura, peripheral neuropathy, abdominal pain, myalgias and arthralgias. MPA is the most common antineutrophil cytoplasmic autoantibodies (ANCA)-associated small-vessel vasculitis. Most patients have positive myeloperoxidase MPOANCA (PANCA), although proteinase 3 PR3 ANCA (CANCA) may be also present. MPA has an incidence of approximately 1:100,000 with a slight predominance in men, and a mean age of onset of about 50 years. Treatment of patients with MPA consists of three
    [Show full text]